The challenges of lupus anticoagulants

References

• Pengo V, Bison E, Denas G, et al. The paradox of the lupus anticoagulant: history and perspectives. Semin Thromb Hemost. 2014;40:860–865.
   PubMed Web of Science ®Google Scholar
• Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295–306.
   PubMed Web of Science ®Google Scholar
• Devreese KM. Antiphospholipid antibody testing and standardization. Int J Lab Hematol. 2014;36:35263,36.
   Google Scholar
• Andreoli L, Chighizola CB, Banzato A, et al. Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. Arthritis Care Res. 2013;65:1869–1873.
   PubMed Web of Science ®Google Scholar
• Pengo V, Ruffatti A, Legnani C, et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost. 2010;8:237–242.
   PubMed Web of Science ®Google Scholar
• Ruffatti A, Del Ross T, Ciprian M, et al. Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up study. Ann Rheum Dis. 2009;68:397–399.
   PubMed Web of Science ®Google Scholar
• Chighizola CB, Andreoli L, De Jesus GR, et al. The association between antiphospholipid antibodies and pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. Lupus. 2015;24:980–984.
   PubMed Web of Science ®Google Scholar
• Galli M, Luciani D, Bertolini G, et al. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood. 2003;101:1827–1832.
   PubMed Web of Science ®Google Scholar
• Reynaud Q, Lega J-C, Mismetti P, et al. Risk of venous and arterial thrombosis according to type of antiphospholipid antibodies in adults without systemic lupus erythematosus: a systematic review and meta-analysis. Autoimmun Rev. 2014;13:595–608.
   PubMed Web of Science ®Google Scholar
• Opatrny L, David M, Kahn SR, et al. Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune disease: a metaanalysis. J Rheumatol. 2006;33:2214–2221.
   PubMed Web of Science ®Google Scholar
• Abou-Nassar K, Carrier M, Ramsay T, et al. The association between antiphospholipid antibodies and placenta mediated complications: a systematic review and meta-analysis. Thromb Res. 2011;128:77–85.
   PubMed Web of Science ®Google Scholar
• De Laat B, Derksen RHWM, et al. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood. 2005;105:1540–1545.
   PubMed Web of Science ®Google Scholar
• Bevers EM, Galli M, Barbui T, et al. Lupus anticoagulant IgG’s (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost. 1991;66:629–632.
   PubMed Web of Science ®Google Scholar
• Oosting JD, Derksen RH, Bobbink IW, et al. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism? Blood. 1993;81:2618–2625.
   PubMed Web of Science ®Google Scholar
• Pengo V, Biasiolo A, Rampazzo P, et al. dRVVT is more sensitive than KCT or TTI for detecting lupus anticoagulant activity of anti-beta2-glycoprotein I autoantibodies. Thromb Haemost. 1999;81:256–258.
   PubMed Web of Science ®Google Scholar
• Pengo V, Balestrieri G, Tincani A, et al. Utilization of dilute Russell’s viper venom time to detect autoantibodies against beta 2-glycoprotein I which express anticoagulant activity in the presence but not in the absence of exogenous phospholipids. Thromb Haemost. 1997;77:123–126.
   PubMed Web of Science ®Google Scholar
• Simmelink MJ, Horbach DA, Derksen RH, et al. Complexes of anti-prothrombin antibodies and prothrombin cause lupus anticoagulant activity by competing with the binding of clotting factors for catalytic phospholipid surfaces. Br J Haematol. 2001;113:621–629.
   PubMed Web of Science ®Google Scholar
• Dienava-Verdoold I, Boon-Spijker MG, De Groot PG, et al. Patient-derived monoclonal antibodies directed towards beta2 glycoprotein-1 display lupus anticoagulant activity. J Thromb Haemost. 2011;9:738–747.
   PubMed Web of Science ®Google Scholar
• Lai CJ, Rauch J, Cho CS, et al. Immunological and molecular analysis of three monoclonal lupus anticoagulant antibodies from a patient with systemic lupus erythematosus. J Autoimmun. 1998;11:39–51.
   PubMed Web of Science ®Google Scholar
• Arnout J, Vanrusselt M, Wittevrongel C, et al. Monoclonal antibodies against beta-2-glycoprotein I: use as reference material for lupus anticoagulant tests. Thromb Haemost. 1998;79:955–958.
   PubMed Web of Science ®Google Scholar
• Sakai Y, Atsumi T, Ieko M, et al. The effects of phosphatidylserine-dependent antiprothrombin antibody on thrombin generation. Arthritis Rheum. 2009;60:2457–2467.
   PubMed Web of Science ®Google Scholar
• Forastiero R, Martinuzzo M, Pombo G, et al. A prospective study of antibodies to beta2-glycoprotein I and prothrombin, and risk of thrombosis. J Thromb Haemost. 2005;3:1231–1238.
   PubMed Web of Science ®Google Scholar
• Chighizola CB, Gerosa M, Meroni PL. New tests to detect antiphospholipid antibodies: anti-domain I beta-2-glycoprotein-I antibodies. Curr Rheumatol Rep. 2014;16:402–409.
   PubMed Web of Science ®Google Scholar
• Takeya H, Mori T, Gabazza EC, et al. Anti-beta2-glycoprotein I (beta2GPI) monoclonal antibodies with lupus anticoagulant-like activity enhance the beta2GPI binding to phospholipids. J Clin Invest. 1997;99:2260–2268.
   PubMed Web of Science ®Google Scholar
• De Laat HB, Derksen RHWM, Urbanus RT, et al. beta2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. Blood. 2004;104:3598–3602.
   PubMed Web of Science ®Google Scholar
• Pengo V, Ruffatti A, Tonello M, et al. Antiphospholipid syndrome: antibodies to Domain 1 of β2-glycoprotein 1 correctly classify patients at risk. J Thromb Haemost. 2015;13:782–787.
   PubMed Web of Science ®Google Scholar
• Pengo V, Ruffatti A, Tonello M, et al. Antibodies to Domain 4/5 (Dm4/5) of β2-Glycoprotein 1 (β2GP1) in different antiphospholipid (aPL) antibody profiles. Thromb Res. 2015;136:161–163.
   PubMed Web of Science ®Google Scholar
• Andreoli L, Chighizola CB, Nalli C, et al. Clinical characterization of antiphospholipid syndrome by detection of IgG antibodies against β2-Glycoprotein I domain 1 and domain 4/5: ratio of anti-domain 1 to anti-domain 4/5 As a useful new biomarker for antiphospholipid syndrome. Arthritis Rheumatol. 2015;67:2196–2204.
   PubMed Web of Science ®Google Scholar
• Agostinis C, Durigutto P, Sblattero D, et al. A non-complement-fixing antibody to β2 glycoprotein I as a novel therapy for antiphospholipid syndrome. Blood. 2014;123:3478–3487.
   PubMed Web of Science ®Google Scholar
• Pregnolato F, Chighizola CB. Phospholipid autoantibodies (non-anticardiolipin)-antiprothrombin antibodies. In: Shoenfeld Y, Gershwin ME, Meroni PL, editors. Autoantibodies. Oxford: Elsevier; 2014. p. 741–749.
   Google Scholar
• Bevers EM, Zwaal RFA, Willems GM. The effect of phospholipids on the formation of immune complexes between autoantibodies and beta2-glycoprotein I or prothrombin. Clin Immunol. 2004;112:150–160.
   PubMed Web of Science ®Google Scholar
• Fleck RA, Rapaport SI, Rao LV. Anti-prothrombin antibodies and the lupus anticoagulant. Blood. 1988;72:512–519.
   PubMed Web of Science ®Google Scholar
• Simmelink MJA, De Groot PG, Derksen RHWM. A study on associations between antiprothrombin antibodies, antiplasminogen antibodies and thrombosis. J Thromb Haemost. 2003;1:735–739.
   PubMed Web of Science ®Google Scholar
• Pengo V, Denas G, Bison E, et al. Prevalence and significance of anti-prothrombin (aPT) antibodies in patients with Lupus Anticoagulant (LA). Thromb Res. 2010;126:150–153.
   PubMed Web of Science ®Google Scholar
• Pregnolato F, Chighizola CB, Encabo S, et al. Anti-phosphatidylserine/prothrombin antibodies: an additional diagnostic marker for APS? Immunol Res. 2013;56:432–438.
   PubMed Web of Science ®Google Scholar
• Arvieux J, Darnige L, Caron C, et al. Development of an ELISA for autoantibodies to prothrombin showing their prevalence in patients with lupus anticoagulants. Thromb Haemost. 1995;74:1120–1125.
   PubMed Web of Science ®Google Scholar
• Pengo V, Tripodi A, Reber G, et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on lupus anticoagulant/antiphospholipid antibody of the scientific and standardisation committee of the international society on thrombosis and haemostasis. J Thromb Haemost. 2009;7:1737–1740.
   PubMed Web of Science ®Google Scholar
• Keeling D, Mackie I, Moore GW, et al. British committee for standards in haematology. Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol. 2012;157:47–58.
   PubMed Web of Science ®Google Scholar
• Ledford-Kraemer MR, Moore GW, Bottenus R, et al. Laboratory testing for the lupus anticoagulant; approved guideline. CLSI Document H60. Wayne (PA): Clinical and Laboratory Standards Institute; 2014.
   Google Scholar
• Rauch J, Tannenbaum M, Janoff AS. Distinguishing plasma lupus anticoagulants from anti-factor antibodies using hexagonal (II) phase phospholipids. Thromb Haemost. 1989;62:892–896.
   PubMed Web of Science ®Google Scholar
• Moore GW. Commonalities and contrasts in recent guidelines for lupus anticoagulant detection. Int J Lab Hematol. 2014;36:364–373.
   PubMed Web of Science ®Google Scholar
• Chantarangkul V, Tripodi A, Arbini A, et al. Silica clotting time (SCT) as a screening and confirmatory test for detection of the lupus anticoagulants. Thromb Res. 1992;67:355–365.
   PubMed Web of Science ®Google Scholar
• Moore GW, Savidge GF. Heterogeneity of Russell’s viper venom affects the sensitivity of the dilute Russell’s viper venom time to lupus anticoagulants. Blood Coagul Fibrinolysis. 2004;15:279–282.
   PubMed Web of Science ®Google Scholar
• Exner T. Conceptions and misconceptions in testing for lupus anticoagulants. J Autoimmun. 2000;15:179–183.
   PubMed Web of Science ®Google Scholar
• Kumano O, Ieko M, Naito S, et al. APTT reagent with ellagic acid as activator shows adequate lupus anticoagulant sensitivity in comparison to silica-based reagent. J Thromb Haemost. 2012;10:2338–2343.
   PubMed Web of Science ®Google Scholar
• Moore GW. Clinical utility of the less commonly employed assays for lupus anticoagulation detection: the evidence. J Coagul Disord. 2010;2:69–79.
   Google Scholar
• Mackie IJ, Lawrie AS, Greenfield RS, et al. A new lupus anticoagulant test based on dilute prothrombin time. Thromb Res. 2004;114:673–674.
   Web of Science ®Google Scholar
• Simmelink MJA, Derksen RHWM, Arnout J, et al. A simple method to discriminate between beta2-glycoprotein I- and prothrombin-dependent lupus anticoagulants. J Thromb Haemost. 2003;1:740–747.
   PubMed Web of Science ®Google Scholar
• Pengo V, Biasiolo A, Pegoraro C, et al. A two-step coagulation test to identify antibeta-glycoprotein I lupus anticoagulants. J Thromb Haemost. 2004;2:702–707.
   PubMed Web of Science ®Google Scholar
• Bertolaccini ML, Amengual O, Andreoli L, et al. 14th international congress on antiphospholipid antibodies task force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimmun Rev. 2014;13:917–930.
   PubMed Web of Science ®Google Scholar
• Oosting JD, Derksen RH, Entjes HT, et al. Lupus anticoagulant activity is frequently dependent on the presence of beta 2-glycoprotein I. Thromb Haemost. 1992;67:499–502.
   PubMed Web of Science ®Google Scholar
• Pennings MTT, De Groot PG, Meijers JCM, et al. Optimisation of lupus anticoagulant tests: should test samples always be mixed with normal plasma? Thromb Haemost. 2014;112:736–742.
   PubMed Web of Science ®Google Scholar
• Chandler JB, Torres R, Rinder HM, et al. Lupus anticoagulant testing and anticoagulation do not mix: quantitation of discrepant results and potential approaches to reduce false positives. Br J Haematol. 2014;167:704–707.
   PubMed Web of Science ®Google Scholar
• Devreese KMJ, De Laat B. Mixing studies in lupus anticoagulant testing are required at least in some type of samples. J Thromb Haemost. 2015;13:1475–1478.
   PubMed Web of Science ®Google Scholar
• Isert M, Miesbach W, Stoever G, et al. Screening for lupus anticoagulants in patients treated with vitamin K antagonists. Int J Lab Hem. 2015;37:758–765. doi:10.1111/ijlh.12409.
   PubMed Web of Science ®Google Scholar
• Kershaw G, Suresh S, Orellana D, et al. Laboratory identification of lupus anticoagulants. Semin Thromb Hemost. 2012;38:375–384.
   PubMed Web of Science ®Google Scholar
• Arachchillage DR, Mackie IJ, Efthymiou M, et al. Interactions between rivaroxaban and antiphospholipid antibodies in thrombotic antiphospholipid syndrome. J Thromb Haemost. 2015;13:1264–1273.
   PubMed Web of Science ®Google Scholar
• Van Os GMA, De Laat B, Kamphuisen PW, et al. Detection of lupus anticoagulant in the presence of rivaroxaban using Taipan snake venom time. J Thromb Haemost. 2011;9:1657–1659.
   PubMed Web of Science ®Google Scholar
• De Groot PG, Lutters B, Derksen RHWM, et al. Lupus anticoagulants and the risk of a first episode of deep venous thrombosis. J Thromb Haemost. 2005;3:1993–1997.
   PubMed Web of Science ®Google Scholar
• Pengo V, Testa S, Martinelli I, et al. Incidence of a first thromboembolic event in carriers of isolated lupus anticoagulant. Thromb Res. 2015;135:46–49.
   PubMed Web of Science ®Google Scholar
• Pengo V, Biasiolo A, Gresele P, et al. A comparison of lupus anticoagulant-positive patients with clinical picture of antiphospholipid syndrome and those without. Arterioscler Thromb Vasc Biol. 2007;27:e309e310.
   Web of Science ®Google Scholar
• Pengo V, Biasiolo A, Gresele P, et al. Survey of lupus anticoagulant diagnosis by central evaluation of positive plasma samples. J Thromb Haemost. 2007;5:925–930.
   PubMed Web of Science ®Google Scholar
• Pengo V, Ruffatti A, Del Ross T, et al. Confirmation of initial antiphospholipid antibody positivity depends on the antiphospholipid antibody profile. J Thromb Haemost. 2013;11:1527–1531.
   PubMed Web of Science ®Google Scholar
• Urbanus RT, Siegerink B, Roest M, et al. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurol. 2009;8:998–1005.
   PubMed Web of Science ®Google Scholar
• Gebhart J, Posch F, Koder S, et al. Increased mortality in patients with the lupus anticoagulant: the Vienna Lupus Anticoagulant and Thrombosis Study (LATS). Blood. 2015;125:3477–3483.
   PubMed Web of Science ®Google Scholar
• Sailer T, Vormittag R, Pabinger I, et al. Inflammation in patients with lupus anticoagulant and implications for thrombosis. J Rheumatol. 2005;32:462–468.
   PubMed Web of Science ®Google Scholar
• Just SA, Nybo M, Laustrup H, et al. Single test isolated lupus anticoagulant positivity is associated with increased plasma levels of inflammatory markers and dyslipidemia. Lupus. 2015;pii:09612033156004040.
   Google Scholar
• Schouwers SME, Delanghe JR, Devreese KMJ. Lupus Anticoagulant (LAC) testing in patients with inflammatory status: does C-reactive protein interfere with LAC test results? Thromb Res. 2010;125:102–104.
   PubMed Web of Science ®Google Scholar
• Reber G, Meijer P. In ECAT veritas?. Lupus. 2012;21:722–724.
   PubMed Web of Science ®Google Scholar
• Cervera R, Asherson RA. Antiphospholipid syndrome associated with infections: clinical and microbiological characteristics. Immunobiology. 2005;210:735–741.
   PubMed Web of Science ®Google Scholar
• Lechner K, Simonitsch I, Haselböck J, et al. Acquired immune-mediated thrombophilia in lymphoproliferative disorders. Leuk Lymphoma. 2011;52:1836–1843.
   PubMed Web of Science ®Google Scholar
• Chighizola CB, Ubiali T, Meroni PL. Treatment of thrombotic antiphospholipid syndrome: the rationale of current management - an insight into future approaches. J Immunol Res. 2015;2015:951424. DOI:10.1155/2015/951424.
   PubMed Web of Science ®Google Scholar